Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas)

EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas)

Mucinex (Guaifenesin) – US: Federal Court grants summary judgment in favour of Perrigo finding no infringement of Adams Respiratory Therapeutics’ Mucinex patent (The IP Factor) (Patent Docs)

Biotech marathon: Vaccines and open innovation, but less IP? (IP Watch)

Exploring a new angle in the TRIPS and drug patents debate (Spicy IP)

EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas)

EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas)

India: Victory for access to medicines as Bayer loses lawsuit in India (GenericsWeb)

India: A comment on the vires of ‘The Protection, Conservation and Effective Management of Traditional Knowledge relating to Biological Diversity Rules, 2009’ (Spicy IP)

Tanzania: Yet another gene patenting storm brewing in Tanzania – Tanzania to oppose US and Brazilian governments from patenting a sorghum gene isolated from a sorghum variety found in Tanzania (Afro-IP)

UK: Satisfying the requirements for industrial applicability – EWCA provides guidance for biotech inventions: Eli Lilly & Co v Human Genome Sciences Inc (IP Think Tank)

UK: EWHC (Pat) finds Merial’s patent relating to ‘method for the in vitro diagnosis of type II porcine circovirus infection and diagnostic reagents’ invalid on grounds of obviousness: Intervet UK Ltd v Merial, the University of Belfast and the University of Saskatchewan (IPKat) (EPLAW)

US: Ariad v Eli Lilly: Written description requirement (Patently-O)

US: An empirical study of the role of the written description requirement in patent prosecution: Ariad v Eli Lilly (Patently-O)

US: Developments up to second-filed application relevant to show no double patenting: Takeda Pharm. Co. v Doll (Filewrapper)

US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs)

US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs)

US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’: Wyeth et al v Abbott Laboratories et al (Docket Report)

US: Monsanto files patent infringement suit against Boggs Farm Center over use of soybean seed produced from earlier planted Roundup Ready soybean seed (Patent Docs)

US: Merck Sharp & Dohme file for review and correction of patent term adjustment calculation in respect of patent covering ‘Substituted pyrazoles, compositions containing such compounds and methods of use’ (Patent Docs)

US: Reverse payments in generic drug settlements – Are the courts or the FTC misapplying the law? (Patent Docs)

US: PhRMA representative questions follow-on biologics paper (Patent Docs)

USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs)

Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs)

Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in Maryland and Delaware following Para IV challenge (Patent Docs)

Detrol (Tolterodine) – US: Teva appeals Pfizer’s win in Detrol patent infringement suit (The IP Factor)

Fentora (Fentanyl) – US: Cephalon files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Fluvastatin – UK: EWCA (Civ) dismisses Novartis’ appeal against High Court’s decision that sustained release fluvastatin patent invalid for obviousness: Actavis v Novartis (EPLAW)

Mucinex (Guaifenesin) – US: Federal Court grants summary judgment in favour of Perrigo finding no infringement of Adams Respiratory Therapeutics’ Mucinex patent (The IP Factor) (Patent Docs)

Niaspan (Niacin) – US: Abbott files patent infringement suits in Delaware and E D Michigan against Sun Pharma following Para IV challenge (Patent Docs)

Patadol (Olopatadine) – US: Alcon files patent infringement suit against Wockhardt in response to Para IV challenge (Patent Docs)

Plavix (Clopidogrel) – US: USPTO tentatively rejects Plavix claims (GenericsWeb)

Seretide (Fluticasone, salmeterol) – South Africa: Commissioner of Patents: Glaxo gets asthma patent relief by claiming Cipla abuse (Afro-IP)

Solodyn (Minocycline) – US: Medicis file patent infringement suit against Ranbaxy following Para IV challenge (Patent Docs)

Viagra (Sildenafil) – US: Board of Patent Appeals affirms rejection of Pfizer’s broad patent over erectile dysfunction treatment (reexam was requested by Lilly & ICOS maker of Cialis and Bayer maker of Levitra): Ex parte Pfizer (Patently-O) (The IP Factor)